Joshua Horan, PhD
Joshua joined the Nuvalent team in June 2018. As Vice President of Nuvalent’s discovery chemistry program, Joshua’s team works with scientific collaborators both in the United States and around the world to identify optimized, small-molecule drug candidates.
Joshua brings over 15 years of drug discovery experience spanning the fields of immunology, nephrology, proteopathy, and oncology. Prior to joining Nuvalent, he was a Senior Principal Scientist of Medical Chemistry at Proteostasis Therapeutics where he worked on high-throughput phenotypic screens and subsequent discovery programs in protein-folding diseases such as Cystic Fibrosis. While at Proteostasis he additionally served as head of the Compound Management group and spearheaded Discovery Informatics. Prior to Proteostasis, he held multiple positions at Boehringer-Ingelheim Pharmaceuticals, most recently serving as Principal Scientist. At Boehringer he worked on a wide range of targets including: LFA-1, S1P1, RORC, BTK, LPA1, and TRPC6.
Joshua earned his PhD in Organic Chemistry from Stanford University.